Does Prednisone Deplete Vitamin D? What the Research Says

Yes, prednisone depletes vitamin D, and this depletion is a central driver of corticosteroid-induced osteoporosis. Prednisone accelerates the enzymatic breakdown of both 25-hydroxyvitamin D (the storage form) and 1,25-dihydroxyvitamin D (the active hormonal form). It also reduces vitamin D receptor expression in target tissues, meaning that even available vitamin D works less effectively. This double hit, faster breakdown plus reduced sensitivity, creates functional vitamin D deficiency that impairs calcium absorption, bone mineralization, and immune function. The vitamin D depletion from prednisone compounds with its direct effects on calcium excretion, creating a cascading mineral imbalance that accelerates bone loss within the first weeks of therapy.

PubMed indexes 14,894 articles on prednisone with 105 meta-analyses, and the vitamin D evidence base includes 74 RCTs across 799,488 patients with 167 meta-analyses. The CTD knowledge graph tracks 1,084 compounds that affect vitamin D biomarker levels, placing prednisone among the clinically significant depletors. FAERS adverse event data consistently links chronic corticosteroid use to vitamin D insufficiency and its downstream consequences including osteoporotic fractures and impaired immune response. Cross-referencing prednisone's 10 confirmed molecular targets at oral doses reveals interactions with NR3C1 (glucocorticoid receptor, Css/IC50 ratio 2,802.7x) and NR3C2 (mineralocorticoid receptor, 737,100x), both of which influence vitamin D metabolism pathways. The American College of Rheumatology explicitly recommends vitamin D supplementation alongside any prednisone course expected to last more than 3 months.

Prednisone depletes vitamin D through three interconnected pathways. First, it induces CYP24A1 (24-hydroxylase), the enzyme responsible for breaking down both 25-hydroxyvitamin D and active 1,25-dihydroxyvitamin D into inactive metabolites. This accelerated catabolism drains vitamin D stores faster than they can be replenished. Second, prednisone downregulates vitamin D receptor (VDR) expression in intestinal epithelial cells, osteoblasts, and immune cells, reducing the biological impact of whatever vitamin D remains. Third, prednisone may impair the renal hydroxylation step that converts 25-hydroxyvitamin D to its active 1,25-dihydroxy form, reducing the production of the most potent form of the vitamin. The net result is a state of functional vitamin D deficiency where both levels and activity are compromised, even in patients with sunlight exposure and dietary intake that would otherwise be adequate.

Begin vitamin D3 supplementation (1000-2000 IU daily) at the start of any prednisone course expected to last more than 2 weeks. For patients already deficient, loading doses of 50,000 IU weekly for 8 weeks may be needed, followed by maintenance dosing. Test 25-hydroxyvitamin D levels at baseline and every 3-6 months during therapy, targeting levels above 40 ng/mL for bone protection. Combine vitamin D with calcium supplementation (1000-1200 mg daily) since vitamin D's primary role is facilitating calcium absorption. Take vitamin D with a fat-containing meal to improve absorption. Fatty fish, fortified dairy products, and egg yolks provide some dietary vitamin D. Moderate sun exposure when possible supports endogenous vitamin D synthesis. Discuss with your healthcare provider whether higher-dose vitamin D or bisphosphonate therapy is appropriate based on your DEXA scan results and fracture risk assessment.